We use cookies to collect anonymous data to help us improve your site browsing experience.

Click 'Accept all cookies' to agree to all cookies that collect anonymous data. To only allow the cookies that make the site work, click 'Use essential cookies only.' Visit 'Set cookie preferences' to control specific cookies.

Set cookie preferences

Your cookie preferences have been saved. You can change your cookie settings at any time.

Publication - Advice and guidance

Thyroid cancer - clinical quality performance indicators: engagement document

Published
9 February 2024
Directorate
Chief Operating Officer, NHS Scotland Directorate
Part of
Health and social care
ISBN
9781835219485

Provides guidance to the thyroid cancer quality improvement indicator engagement document. The survey can be accessed on our Citizen Space engagement document.

View supporting documents Supporting documents

9. References

  • Scottish Government (2016). Beating Cancer: Ambition and Action (accessed December 2016). Available online from: https://www.gov.scot/publications/beating-cancer-ambition-action/
  • NHS Quality Improvement Scotland (2008). Management of Core Cancer Services Standards.
  • Abdulrahman GO Jr. The effect of multidisciplinary team care on cancer management. Pan Afr Med J. 2011;9:20. doi: 10.4314/pamj.v9i1.71195. Epub 2011 Jun 17. PMID: 22355430; PMCID: PMC3215542.
  • Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. (2012) BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore). 2012 Sep;91(5):274-286. doi: 10.1097/MD.0b013e31826a9c71. PMID: 22932786.
  • Vuong HG, Altibi AMA, Duong UNP, Hassell L. (2017) Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clin Endocrinol (Oxf). 2017 Nov;87(5):411-417. doi: 10.1111/cen.13413. Epub 2017 Aug 2. PMID: 28666074.
  • Lorenz K, Raffaeli M, Barczyński M, Lorente-Poch L, Sancho J. (2020) Volume, outcomes, and quality standards in thyroid surgery: an evidence-based analysis-European Society of Endocrine Surgeons (ESES) positional statement. Langenbecks Arch Surg. 2020 Jun;405(4):401-425 (accessed October 2023). Available online from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275525/
  • Gray WK, Aspinall S, Tolley N, Day J, Lansdown M. (2021) The volume and outcome relationship for thyroidectomy in England. Langenbecks Arch Surg. 2021 Sep;406(6):1999-2010 (accessed October 2023) Available online from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8188540/
  • Dueñas JP, Duque CS, Cristancho L, Méndez M (2020). Completion thyroidectomy: is timing important for transcervical and remote access approaches? World J Otorhinolaryngol Head Neck Surg. 2020 Jun 30;6(3):165-170. doi: 10.1016/j.wjorl.2020.02.006 (accessed October 2023). Available online from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548381/
  • NICE (2022): Thyroid Cancer: Assessment and Management NG230 (accessed October 2023). Available online from: https://www.nice.org.uk/guidance/NG230
  • Sun Y, Sun Q, Tian J, He X. (2023) Impact of waiting time for radioactive iodine therapy on outcome in N1 stage papillary thyroid cancer. J Clin Endocrinol Metab. 2023 May 11:dgad264. doi: 10.1210/clinem/dgad264. Epub ahead of print. PMID: 37167097
  • Yu F, Li X, Ji Y, et al. (2021) Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer. Front Endocrinol (Lausanne). 2021 Nov 9;12:743310. doi: 10.3389/fendo.2021.743310. PMID: 34858329; PMCID: PMC8630653.
  • Perros P, 2014, Guidelines for management of thyroid cancer, Clinical Endocrinology, Vol 81, Suppl 1, July 2014.
  • NICE (2022): Thyroid Cancer: Assessment and Management NG230 (accessed October 2023). Available online from: https://www.nice.org.uk/guidance/ng230
  • Bible KC, Kebebew E, Brierley J et al. (2021) American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid 31:337 - 386 (accessed October 2023). Available online from: https://www.liebertpub.com/doi/full/10.1089/thy.2020.0944
  • Jannin A et al. (2022) Anaplastic Thyroid Carcinoma: An Update. Cancers (Basel). 2022 Feb 19;14(4):1061. doi: 10.3390/cancers14041061. PMID: 35205809; PMCID: PMC8869821 (accessed October 2023). Available online from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869821/
  • Molinaro, E., Romei, C., Biagini, A. et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat Rev Endocrinol 13, 644-660 (2017) (accessed October 2023. Available online from https://doi.org/10.1038/nrendo.2017.76
  • Cabanillas M, Zafereo M, Williams MD, Ferrarotto R, Dadu R, Gross N, Gunn GB, Skinner H, Cote G, Grosu HB, Iyer P, Busaidy NL. Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000 Res. 2018;7:87.
  • Endocrine Reviews 2019 Dec; 40(6): 1573-1604 - Targeted Therapy for Advanced Thyroid Cancer (accessed October 2023). Available online from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341904/

Contact

Email: cancerpolicyteam@gov.scot

Back to top